Loading stock data…
$0.87+0.01 (+1.14%)
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States.
Allarity Therapeutics, Inc. in the Healthcare sector is trading at $0.87 with a market capitalization of $16M. Wall Street consensus targets $11.00 (1 analysts), implying a +1164.5% move over the next 12 months. The stock is currently near its 52-week low of $0.77, remaining 29.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $25,000↓ | $320,000 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.67M↑ | -$2.69M↑ | -$2.92M↓ | -$2.52M↑ | -$4.13M |
| Net Income | -$3.40M↓ | -$2.75M↑ | -$3.37M↓ | -$2.81M↓ | -$2.32M |
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the persona...